Alan Horsager, Ph.D. is a life science executive developing genetic medicines for human diseases. His career has been dedicated to early-stage development, translating cutting-edge technologies from academic labs to clinical applications. Dr. Horsager currently serves as the President, CEO, and Director of Duet BioTherapeutics and the President,. Immuno-Oncology of Scopus BioPharma.. At Duet BioTherapeutics, Dr. Horsager leads the effort in developing targeted bifunctional immunotherapies designed to combat treatment-resistant cancers. These groundbreaking immunotherapies reprogram immune cells within the tumor microenvironment, reinvigorating the immune system's natural cancer-fighting capabilities.. Prior to his roles at Duet and Scopus, Dr. Horsager was a Consultant at L.E.K. Consulting, a premier strategy consulting firm serving the life sciences sector where he focused on oncology diagnostics and provided strategic insights to top biotechnology and pharmaceutical companies.. Prior to L.E.K., Dr. Horsager was President, CEO, and Co-Founder of Episona, where he led a team in developing a pioneering epigenetic-based molecular diagnostic test for infertility and other human diseases. Through multi-center trials, he validated the clinical utility of the test, secured substantial private investment, and cultivated strategic relationships that facilitated the test's international distribution to in-vitro fertility clinics and direct-to-consumer.. Before his move into entrepreneurship, Dr. Horsager served as a Research Assistant Professor at the University of Southern California. In this role, he led a gene therapy and vision science laboratory, where he focused on developing optogenetic-based gene therapies for blindness and advancing our understanding of retinal degeneration. His collaborative work with investigators at the University of Florida and MIT yielded patents, scientific publications, and recognition through career awards, including the Coulter Foundation Translational Research Award and The Burroughs Wellcome Fund CASI Award.. Dr. Horsager earned a Ph.D. in Neuroscience from the University of Southern California and a B.A. in Psychology from the University of Washington. His Ph.D. research centered around developing computational models of visual processing in blind patients, leading to patented technologies and the creation of a clinically approved device for treating retinitis pigmentosa.
